TSL2109: A Novel Dual-Target Cancer Drug for Resistant Prostate Cancer

TSL2109 is an experimental oral cancer drug being studied in people with advanced solid tumors, especially metastatic castration-resistant prostate cancer (aka androgen pathway modulation resistant prostate cancer, or APMR, God save us!) and advanced hormone receptor–positive, HER2-negative breast cancer. It is designed to hit two important targets at once, CDK4/6 and DYRK2, which may help it slow tumor growth in a different way from older treatments. The main idea is to block the signals that tell cancer cells to keep dividing.

What makes TSL2109 interesting is that it may work even when cancers become resistant to other drugs. In laboratory studies, it lowered several proteins linked to cell division and ribosome production, while increasing p53, a protein that helps damaged cells stop growing or die. That matters because many cancers escape treatment by finding backup pathways, and TSL2109 appears designed to interrupt some of those escape routes.

The strongest early data come from preclinical studies in prostate cancer. In models that no longer responded well to enzalutamide, TSL2109 still showed antitumor activity in cells, organoids, and mouse tumors. This suggests it could eventually help men whose prostate cancer has progressed after hormone-targeted treatment.

The same logic may also apply to breast cancer. CDK4/6 inhibitors are already important drugs in HR+/HER2- breast cancer, but resistance is a common problem. By affecting both CDK4/6 and DYRK2, TSL2109 may reduce the tumor’s ability to adapt after CDK4/6 therapy stops working.

The current human study is a phase 1 trial, so its main goal is safety, dose finding, and early signs of activity. Participants take the drug by mouth on an empty stomach, first in a short single-dose observation period and then in repeated 28-day cycles. Treatment can continue as long as side effects are manageable and there may still be benefit.

Clinical trial.